Silver Book Fact

Effectiveness of an oral pharmacologic agent in preventing venous thrombosis

An oral pharmacologic agent has been demonstrated to be at least as effective as an injectable anticoagulant in the prevention of venous thrombosis following hip replacement.

Eriksson B, Dahl O, Rosencher N, Kurth A, et al. Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591): 949-56. http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2961445-7/fulltext

Reference

Title
Dabigatran Etexilate Versus Enoxaparin for Prevention of Venous Thromboembolism After Total Hip- Replacement: A randomised, double-blind, non-inferiority trial
Publication
Lancet
Publication Date
2007
Authors
Eriksson B, Dahl O, Rosencher N, Kurth A, et al.
Volume & Issue
Volume 370, Issue 9591
Pages
949-56
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Increased Use of Medicines Reduces Risk of Death After Major Cardiovascular Events: Disease management program increased use of medicines  
  • Pioglitazone associated with relative risk reduction in recurrent stroke
    The PROactive trial to manage glucose in diabetics with a history of cardiovascular disease, stroke, or other vascular risk factors found that treatment with pioglitazone was associated with a 47% relative…  
  • It is estimated that the number of quality-adjusted life-years achieved with each $1 million spent on antihypertensive drug therapy is between 20-50 to more than 200.  
  • Eliminating out-of-pocket drug costs for combination pharmacotherapy for the 423,000 Americans with drug insurance who will experience their first myocardial infarction in 2006 would save 4,736 lives, and would save…  
  • Following the current path, pulmonary condition cases will increase by 31.3% between 2003 and 2023. If an alternative path is taken, there will be 9.1% fewer pulmonary condition cases.